Immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1 (PD‐1), programmed cell death 1 ligand 1 (PD‐L1), and cytotoxic T lymphocyte antigen 4 (CTLA‐4) immune checkpoints have made rapid progress in ccRCC treatment. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.